The DOI matches its Crossref record.
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Abstract
OBJECTIVE: NIDDM occurs commonly among women with polycystic ovary syndrome (PCOS). The prevalence and natural history of its precursor, impaired glucose tolerance (IGT), is less well known. The objective of this study was to characterize the prevalence and incidence of glucose intolerance in a large cohort of women with well-characterized PCOS. RESEARCH DESIGN AND METHODS: A total of 122 women with clinical and hormonal evidence of PCOS were recruited from the Medicine, Endocrinology, Gynecology, and Pediatrics Clinics at the University of Chicago. All women had a standard oral glucose tolerance test (OGTT) with measurement of glucose and insulin levels. A subset of 25 women were subsequently restudied with the aim of characterizing the natural history of glucose tolerance in PCOS. RESULTS: Glucose tolerance was abnormal in 55 (45%) of the 122 women: 43 (35%) had IGT and 12 (10%) had NIDDM at the time of initial study. The women with NIDDM differed from those with normal glucose tolerance in that they had a 2.6-fold higher prevalence of first-degree relatives with NIDDM (83 vs. 31%, P < 0.01 by chi 2) and were significantly more obese (BMI 41.0 +/- 2.4 vs. 33.4 +/- 1.1 kg/m2, P < 0.01). For the entire cohort of 122 women, there was a significant correlation between fasting and 2-h glucose concentrations (r = 0.76, P < 0.0001); among the subset with IGT, the fasting glucose concentration was poorly predictive of the 2-h level (r = 0.25, NS). After a mean follow-up of 2.4 +/- 0.3 years (range 0.5-6.3), 25 women had a second OGTT. The glucose concentration at 2 h during the second glucose tolerance test was significantly higher than the 2-h concentration during the first study (161 +/- 9 vs. 139 +/- 6 mg/dl, P < 0.02). CONCLUSIONS: The prevalence of IGT and NIDDM in women with PCOS is substantially higher than expected when compared with age- and weight-matched populations of women without PCOS. The conversion from IGT to NIDDM is accelerated in PCOS. The fasting glucose concentration does not reliably predict the glucose concentration at 2 h after an oral glucose challenge, particularly among those with IGT, the subgroup at highest risk for subsequent development of NIDDM. We conclude that women with PCOS should periodically have an OGTT and must be closely monitored for deterioration in glucose tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In women with PCOS, dysglycemia typically consists of impaired glucose tolerance [12], its prevalence being of almost 30% in both adult women [13] and affected adolescents [14].”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [13]
In the citing paper
“Earlier-onset hyperglycaemia and rapid progression to DM2 is also reported in PCOS. 104,105”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [104]
Citations
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Familial aggregation of circulating c-reactive protein in polycystic ovary syndrome
Sasidevi, A., Vellanki, P., Kunselman, A. R., Raja-Khan, N. T., Dunaif, A. E., & Legro, R. S. (2012) · Human Reproduction · doi:10.1093/humrep/des416 · Cited by 5
“In PCOS, impaired glucose tolerance is more prevalent than impaired fasting glucose (Ehrmann et al., 1999).”
BackgroundRisk of impaired glucose tolerance in normal weight hirsute women during four years observation
Andries, M., Glintborg, D., & Andersen, M. (2010) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016341003801680 · Cited by 5
“In cross-sectional studies women with PCOS had a 5–10 times increased risk of diabetes (4,5) and a high conversion rate from normal to impaired glucose tolerance or type 2 diabetes (4,6,7).”
BackgroundAngiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome
DEEDWANIA, P. C., & Schmieder, R. E. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.018 · Cited by 5
Should patients with polycystic ovarian syndrome be treated with metformin
Nestler, J. E. (2002) · Cited by 5
Phenotypes Associated With Polycystic Ovary Syndrome Risk Variants
Tidwell, A. J., Zhu, J., Battiola, T., & Welt, C. K. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae219 · Cited by 5
Involvement of Bone Morphogenetic Proteins (BMPs) in Ovarian Function and Infertility
Vireque, A. A., dos Reis, R. M., Silva, A. A. M. R. E., de Resende, L. O. T., Ferreira, E. M., Silva, A. C. J. S. R. E., & Ferriani, R. A. (2008) · The Open Reproductive Science Journal · doi:10.2174/1874255600801010011 · Cited by 4
“POS has been defined as a syndrome involving polycystic ovaries, hyperandrogenism, and chronic anovulation, with the exclusion of specific diseases of the ovaries, adrenal glands and pituitary [58].”
BackgroundInfluentialHussein, I., El-Shahawy, A. A. S., & Awwad, H. (2020) · Evidence Based Women s Health Journal · doi:10.21608/ebwhj.2019.18307.1042 · Cited by 4
“Hyperinsulinaemia, insulin resistance and impaired glucose tolerance are very common in women with PCOS, particularly in those with a body mass index (BMI) > 30 Kg/m2[3].”
BackgroundAltemimi, M. T., musa, A. K., & Mansour, A. A. (2021) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v13i2.1431 · Cited by 4
Krstevska, B., Mishevska, S. J., Nakova, V. V., & Serafimoski, V. (2021) · PRILOZI · doi:10.2478/prilozi-2021-0022 · Cited by 4
“in 1999 for the first time [12] and was confirmed by Shorakae et al.”
ResultDiet and exercise in the management of PCOS: Starting from the basics
Markantes, G. Κ., Tsichlia, G., & Georgopoulos, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00010-9 · Cited by 5
Pan, M.-L., Chen, L.-R., & Chen, K.-H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095470 · Cited by 4
“It is also associated with other metabolic syndromes including dyslipidemia and increases the long-term risk of type 2 diabetes mellitus [2,9,10].”
BackgroundWu, R., & Gragnoli, C. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01567-1 · Cited by 4
Defining prediabetes in polycystic ovarian syndrome
Trolice, M. P. (2011) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2011.12008 · Cited by 5
“6% present with T2DM [46-48].”
Ramanand, S. J., Ramanand, J. B., Raparti, G., Ghanghas, R. R., Halasawadekar, N. R., Patil, P. T., Pawar, M., & Shinde, M. (2014) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.5455/2320-1770.ijrcog20140324 · Cited by 4
Screening for glycaemic abnormalities in PCOS: an ongoing controversy
Teede, H. J., Harrison, C. L., & Zoungas, S. (2013) · Human Reproduction · doi:10.1093/humrep/det227 · Cited by 3
“Finally, as women with PCOS are also more prone to obesity, dyslipidemia and potentially hypertension, the additive effect of glycaemic abnormalities (both prediabetes and DM2) to these other risk factors, augments overall metabolic risk and mandates more aggressive screening and intervention.”
BackgroundInfluentialPolycystic Ovarian Syndrome Burden in Central India: A Cross-Sectional Study
Sridevi, P., Singh, K. R., Sree Lekshmi, K. K., Manasingh, D., & Badajena, S. (2020) · Journal of Clinical Research and Reports · doi:10.31579/2690-1919/095 · Cited by 4
“PCOS affected women with frequent risk of developing type 2 diabetes at an occurrence of 3-7 times [8, 9].”
BackgroundHandelsman, R. G., Wertheimer, S., VanHise, K., Buttle, R. A., Clark, E. L., Wang, E. T., Azziz, R., Pisarska, M. D., & Chan, J. L. (2022) · F&S Reports · doi:10.1016/j.xfre.2022.09.004 · Cited by 4
Polycystic ovary syndrome in North America
Shahid, M., & Wajid, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00039-6 · Cited by 4
Bridging the Gap: Integrating Awareness of Polycystic Ovary Syndrome Into Mental Health Practice
Standeven, L. R., Ho, A., & Hantsoo, L. V. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20230024 · Cited by 5
Ruby, L. A. (2008) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2008.08.005 · Cited by 4
MCP-1 and fetuin A levels in patients with PCOS and/or obesity before and after metformin treatment
Gateva, A., Kamenov, Z. A., & Tsakova, A. D. (2013) · Open Medicine · doi:10.2478/s11536-012-0149-y · Cited by 4
“According to some studies, PCOS patients have an increased risk for diabetes mellitus [1,2] and often show an adverse cardiovascular risk profile – increased rate of arterial hypertension [3,4], dislipidemia [4-7] and subclinical inflammation and atherosclerosis [8-10].”
BackgroundPrevalence of glucose tolerance test abnormalities in women with polycystic ovarian syndrome
Gracelyn, L., & Pushpagiri, N. (2015) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20151215 · Cited by 4
Stassek, J., Erdmann, J., Ohnolz, F., Berg, F., Kiechle, M. B., & Seifert‐Klauss, V. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0042-119199 · Cited by 4
Metformin as a Weight-Loss Tool in “At-Risk” Obese Adolescents: A Magic Bullet?
Kasa-Vubu, J. Z. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.03.006 · Cited by 4
Alcoser, S. Y., Hara, M., Bell, G. I., & Ehrmann, D. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031189 · Cited by 4
“Fourteen (12%) of the subjects were diabetic, consistent with the increased prevalence of diabetes in PCOS (1, 2).”
BackgroundSelf-citationRisques à long terme du syndrome des ovaires polykystiques
Lefebvre, P., Raingeard, I., Renard, É., & Bringer, J. (2004) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2003.07.010 · Cited by 4
del Río, M. J., V, Ramírez-Mahaluf, J. P., Cortés, M. E., Gerardo Martí, O., Ana Godoy, R., & Pilar Vigil, P. (2006) · Revista chilena de obstetricia y ginecología · doi:10.4067/s0717-75262006000500002 · Cited by 4
Insulin resistance in polycystic ovary syndrome: maker or marker?
Bozdağ, G., & Yıldız, B. O. (2009) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.09.73 · Cited by 4
Papaleo, E., Molgora, M., Quaranta, L., Pellegrino, M., & de Michele, F. (2011) · PubMed · Cited by 4
Nonalcoholic fatty liver disease in young adult Egyptian women with polycystic ovary syndrome
Eldesoky, A.-E., Gad, Y. Z., & Ahmed, N. A. F. (2013) · Egyptian Liver Journal · doi:10.1097/01.elx.0000424245.18235.1e · Cited by 4
Karadağ, C., & Yoldemir, T. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1603213 · Cited by 4
“Glucose and lipid disorders were detected in lean PCOS patients previously (Morales et al. 1996; Ehrmann et al. 1999).”
BackgroundPolycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00020-6 · Cited by 5
Advances in the treatment of polycystic ovary syndrome
Moghetti, P. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1631 · Cited by 4
“Altered glucose tolerance is approximately 7-fold more common in PCOS women than in the age-matched general population; this risk being particularly high in obese subjects [9-10].”
BackgroundDiamanti‐Kandarakis, E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_32 · Cited by 4
Up-to-date Definition of the Polycystic Ovary and Polycystic Ovary Syndrome
Hamzeh, R., & Balen, A. H. (2006) · Ultrasound · doi:10.1179/174313406x120477 · Cited by 4
Ahmadieh, H., Aboudib, K., Dassouki, W., Charbaji, L., El-Dassouki, M. A. A., & Khalaf, I. A. (2021) · Research Square · doi:10.21203/rs.3.rs-395164/v1 · Cited by 4
Regidor, P., de la Rosa, X., Mueller, A., Sailer, M., Santos, F. G., Banzo, R. G., & Rizo, J. M. (2021) · Preprints.org · doi:10.20944/preprints202108.0473.v1 · Cited by 3
Mohammed, S., Sundaram, V., Cockburn, B. N., Motilal, S., Ottey, S., & Azziz, R. (2025) · Women s Health Reports · doi:10.1089/whr.2025.0008 · Cited by 3
Berbrier, D. E., Huckins, W., Berkel, E. K. V., Delage, S. I., Hannaian, S. J., Myara, R., Okafor, O. N., Chung, T. H., Tulandi, T., Reinblatt, S. L., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00286.2025 · Cited by 3
Bunyapipat, P., Klangsin, S., Peeyananjarassri, K., Wattanakumtornkul, S., Katesuwan, S., Geater, A. F., & Numit, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70126 · Cited by 3
“8 These discrepancies may be attributed to differences in baseline characteristics, particularly the lower BMI and the relatively small sample size of our cohort.”
Andavar, M., Kamaraj, R., Vijayakumar, T. M., & Murugesan, A. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2358237 · Cited by 3
Recent trends in polycystic ovary syndrome treatment based on adult stem cell therapies
Park, H., Han, J. W., & Kim, G. J. (2025) · Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine · doi:10.5653/cerm.2024.07248 · Cited by 3
“In addition to reproductive challenges, women with PCOS are at an increased risk of developing type 2 diabetes (T2D) and insulin dysfunction [15,16].”
Diagnóstico etiológico do hirsutismo e implicações para o tratamento
Spritzer, P. M. (2009) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/s0100-72032009000100008 · Cited by 3
Hyperandrogenism in Women: Polycystic Ovary Syndrome
Sung, Y. (2012) · Hanyang Medical Reviews · doi:10.7599/hmr.2012.32.4.197 · Cited by 3
“높았으며 이는 과거 다른 인종의 결과와 비교하여 큰 차이가 없었다 [29-32].”
Oral contraceptives in polycystic ovarian syndrome: the long and short of it
Nader, S. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.88 · Cited by 3
A Literature Review of the Effects of PCOS on Cardiovascular Health
Mundle, K., & Raza, Z. (2021) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.238 · Cited by 3
“study found that after the administration of the nafarelin, the individuals with PCOS had a similar hormonal response pattern as men which was seen through increased production of 17α-hydroxyprogesterone in both groups [29].”
BackgroundInfluentialSneeringer, R. M., & Moragianni, V. A. (2011) · Reproductive medicine and assisted reproductive techniques series · doi:10.3109/9781841848181.012 · Cited by 3
Shah, M. I., Buscot, M., Tian, J., Phan, H., Marwick, T. H., Dwyer, T., Venn, A., & Gall, S. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.077 · Cited by 4
Comorbidities of Childhood Obesity
Banerjee, A., & Dara, P. (2012) · InTech eBooks · doi:10.5772/33612 · Cited by 3
“…like resistin, adipsin and others which are believed to be the missing link between obesity and target tissue resistance to insulin resulting in Type DM. [35-37] With early onset of obesity, the population is believed to be more susceptible to the disease and its inadvertent complications.”
Role in Reproductive Biology and Reproductive Dysfunction in Women
Pal, L., & Taylor, H. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809965-0.00043-4 · Cited by 3
van Santbrink, E. J. P. (2009) · Springer eBooks · doi:10.1007/978-0-387-09718-3_20 · Cited by 3
Javed, A., Lteif, A. N., Kumar, S., Simmons, P. S., & Chang, A. Y. (2015) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2015.01.001 · Cited by 5
Therapy for polycystic ovarian syndrome
WEI, A., & Pritts, E. A. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.06.004 · Cited by 3
Prevalence of Metabolic Syndrome in Young Korean Women with Polycystic Ovary Syndrome
Lee, H., Oh, J. Y., Hong, Y.-S., Sung, Y., & Chung, H. (2006) · The Journal of Korean Diabetes Association · doi:10.4093/jkda.2006.30.4.285 · Cited by 3
Cobin, R. H. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.259 · Cited by 3
Omental Fat Receptor Interacting Protein 140 mRNA Expression in Women with Polycystic Ovary Syndrome
Seow, K., Tsai, Y.-L., Juan, C., Huang, L., Hwang, J., & Ho, L. (2009) · Gynecologic and Obstetric Investigation · doi:10.1159/000253852 · Cited by 3
Toward a new approach: primary and preventive care of the woman with polycystic ovarian syndrome
Ahles, B. L. (2000) · Primary Care Update for OB/GYNS · doi:10.1016/s1068-607x(00)00059-7 · Cited by 3
Marked insulin resistance in pregnancy
Evans, K., & Millward, B. A. (2006) · Practical Diabetes · doi:10.1002/pdi.917 · Cited by 3
The metabolic effects of drugs used for the treatment of polycystic ovary syndrome
Karaköse, M., Çakal, E., Ertan, K., & Delibaşı, T. (2013) · Journal of the Turkish-German Gynecological Association · doi:10.5152/jtgga.2013.57701 · Cited by 3
“Other clinical conditions related to PCOS include impaired glucose tolerance (IGT), type 2 diabetes mellitus (24), metabolic syndrome (20-23), non-alcoholic steatohepatitis (14), sleep apnea syndrome (25), malignancy (endometrium, ovary, breast cancer) (14, 26) and increased cardiovascular risk (27-29).”
The link between polycystic ovary syndrome and Type 2 diabetes: what do we know today?
Sathyapalan, T., & Atkin, S. L. (2011) · Diabetes Management · doi:10.2217/dmt.11.59 · Cited by 3
PCOS and metformin: from pharmacology to clinical use for women's health
Genazzani, A. D., Ricchieri, F., Prati, A., Chierchia, E., Rattighieri, E., Bosco, G., Despini, G., Campedelli, A., Farinetti, A., & Santagni, S. (2012) · IRIS UNIMORE (University of Modena and Reggio Emilia) · Cited by 3
Dziuba, M., Jander, S., Zwoliński, R., & Chiżyński, K. (2009) · Archives of Medical Science · Cited by 3
Clinical Evaluation of Polycystic Ovary Syndrome
Taylor, A. E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_31 · Cited by 3
Polycystic Ovary Syndrome and the Relationship of Cardiovascular Disease Risk
Çakır, E., Çakal, E., Özbek, M., Şahi̇n, M., & Delibaşı, T. (2013) · Endocrinology research and practice. · doi:10.4274/tjem.2071 · Cited by 3
NT-proBNP levels in premenopausal women with polycystic ovarian syndrome and/or obesity
Gateva, A., Kamenov, Z. A., & Tsakova, A. D. (2013) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2013.813912 · Cited by 3
“According to some studies, PCOS patients have an increased risk for diabetes mellitus (Ehrmann et al. 1999; Legro et al. 1999) and oft en show an adverse cardiovascular risk profi le, i.e. an increased rate of arterial hypertension (Bjorntorp 1996; Vrb í kov á et al. 2003); dislipidaemia (Wild et…”
Result[The metabolic aspects of polycystic ovarian syndrome].
Skałba, P., & Dąbkowska-Huć, A. (2005) · PubMed · Cited by 3
STUDY OF ADOLESCENT GIRLS WITH MENSTRUALIRREGULARITIES FOR POLYCYSTIC OVARIES AND INSULIN RESISTANCE
Kumari, S., Pankaj, S., Kavita, K., Choudhary, V., & Raghwendra, K. H. (2015) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2015/802 · Cited by 3
Predictors of Metabolic Syndrome among Polycystic Ovary Syndrome Sisters
Kulshreshtha, B., Sharma, N., Pant, S., Prasad, A., Chitkara, A., Pahuja, B., & Pahuja, I. (2019) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_172_18 · Cited by 3
Azziz, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-69248-7_8 · Cited by 3
Insulin Sensitizers Targeting Metabolic and Reproductive Consequences in Polycystic Ovary Syndrome
Diamanti‐Kandarakis, E. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-108-6_13 · Cited by 3
Dunaif, A. E., & Legro, R. S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5939-4 · Cited by 3
Polycystic ovarian syndrome and insulin resistance: a South Indian study
Anuradha, V., Gangadharan, K., Saxena, R. K., & Krishna, L. (2020) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20201054 · Cited by 2
Yan, Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/kpne-0v56 · Cited by 3
Hiperandrogenismo en la mujer diabética: rol de la resistencia insulínica y de la hiperinsulinemia
Tejada, G. G.-R. D., & Escobar-Morreale, H. F. (2003) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(03)74555-0 · Cited by 3
Metformin in polycystic ovary syndrome
Moll, E. (2013) · UvA-DARE (University of Amsterdam) · Cited by 3
Murray, R. (2002) · Diabetes Spectrum · doi:10.2337/diaspect.15.4.227 · Cited by 3
Ludwig, M. Z., & Epe, M. (2005) · Gynäkologische Endokrinologie · doi:10.1007/s10304-005-0105-x · Cited by 3
Polycystic Ovary Syndrome and Cardiovascular Disease
Corenblum, B. (2001) · Journal SOGC · doi:10.1016/s0849-5831(16)30985-5 · Cited by 3
Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018) · Endocrine Abstracts · doi:10.1530/endoabs.56.gp127 · Cited by 3
Body Mass and Depression among Mississippi Women with Polycystic Ovarian Syndrome
Bruce, L. A. (2014) · Aquila Digital Community (University of Southern Mississippi) · Cited by 3
Pasquali, R., & Gambineri, A. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_30 · Cited by 3
Niepsuj, J., Piwowar, A., Franik, G., & Bizoń, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010331 · Cited by 2
“Given that approximately 30–40% of women with PCOS exhibit impaired glucose metabolism, IR, or T2D [36–38], the TyG index has been proposed as a useful tool to distinguish metabolic from non-metabolic PCOS phenotypes [39–41].”
Hamsho, M., Shkorfu, W., Bensaoua, M., Martins, C. E. C., Hacıbayram, H., Fadel, A., & Ranneh, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1802369 · Cited by 2
Yurtseven, K., Akbaba, A. K., Pınarlı, Ç., İbanoğlu, M. C., & Üstün, Y. E. (2026) · BMC Women s Health · doi:10.1186/s12905-026-04628-3 · Cited by 2
“Again, for prediabetes, many scientific authorities consider a fasting glucose of 100–125 mg/dL as “impaired fasting glucose” and a 2nd hour plasma glucose of 140–199 mg/dL and HbA1c of 5.7–6.4% on the OGTT to indicate prediabetes [31–33].”
InfluentialNew onset of alopecia in a young woman with end-stage renal disease
Pistrosch, F., Herbrig, K., Parmentier, S. B., & Gross, P. (2008) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfn031 · Cited by 2
“PCOS may be associated with impaired glucose tolerance in up to 50% of patients [5].”
BackgroundThe pediatric origins of polycystic ovary syndrome
Roldán, B., & Escobar-Morreale, H. F. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545191.015 · Cited by 2
Singh, P., Biswal, S., & Verma, S. K. (2020) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20205220 · Cited by 2
“Several studies suggest that some abnormal action of insulin might be dependent from the inositolphosphoglycan (IPG) mediators of insulin action and suggest that a deficiency in a specific D-chiroinositol (DCI)- containing IPG may underlie insulin resistance, similarly to type 2 diabetes.(7)”
BackgroundPolycystic ovary syndrome in middle-aged women: associated diseases
Zaidieva, Y. Z., & Дмитриевна, К. В. (2022) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush20222201145 · Cited by 2
СИНДРОМ ПОЛІКІСТОЗНИХ ЯЄЧНИКІВ: РОЛЬ УЛЬТРАЗВУКОВОЇ ДІАГНОСТИКИ
Markin, L. B., & Matvienko, O. O. (2020) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2019.2.10922 · Cited by 2
Legro, R. S. (2007) · Springer eBooks · doi:10.1007/978-0-387-69248-7_2 · Cited by 2
Bagegni, N. A., Blaine, J., Voorhis, B. J. V., & Dokras, A. (2010) · Proceedings in Obstetrics and Gynecology · doi:10.17077/2154-4751.1050 · Cited by 2
Wheeler, C. J., Keye, W. R., & Peterson, C. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1436-1_11 · Cited by 2
Polycystic Ovary Syndrome and Its Metabolic Complications
Liao, E. P., & Poretsky, L. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-985-1_15 · Cited by 2
Menstrual Disorders and Hyperandrogenism in Adolescence
DiVall, S. A., & Rosenfield, R. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-395-4_25 · Cited by 2
Self-citationVieira, C. S., Gomes, M. K. O., Rodrigues, P. C., Pinto, A. P. M., dos Reis, R. M., Ferriani, R. A., & de Sá, M. F. S. (2007) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/s0100-72032007000300005 · Cited by 2
Manifestaciones clínica del síndrome del ovario poliquístico
Morales, D. F. (2009) · Acta Médica Costarricense · doi:10.51481/amc.v47i4.204 · Cited by 2
Prevalence of abnormal glucose metabolism in a cohort of Arab women with polycystic ovary syndrome
Abdel-Rahman, M., Abdellah, A. H., Ahmad, S. R., Ismail, S. A., Frasure, H. E., & Hurd, W. W. (2011) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2011.03.019 · Cited by 2
“0001) (Table 2)—results that are consistent with those indicated in studies from other regions [8].”
BackgroundResultInfluentialRole of hyperinsulinemic insulin resistance in polycystic ovary syndrome
Iuorno, M. J. (2001) · Polycystic Ovary Syndrome · doi:10.1017/cbo9780511545191.013 · Cited by 3
(2009) · PubMed · Cited by 160
(2012) · Europe PMC (PubMed Central) · Cited by 13
Metadata
- Authors
- Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J.
- Affiliations
- University of Chicago (US)
- ORCID
- Rosenfield, R L
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1999-01-01
- Volume
- 22
- Issue
- 1
- Pages
- 141-146
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2007816906
- Cited by
- 1,257
- References
- 0
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 22 · 2023: 18 · 2022: 39 · 2021: 45 · 2020: 32 · 2019: 39 · 2018: 40 · 2017: 45 · 2016: 37 · 2015: 63 · 2014: 63 · 2013: 55 · 2012: 75
- FWCI
- 31.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- polycystic ovary syndrome, impaired glucose tolerance, type 2 diabetes, prevalence, incidence, natural history (disease), oral glucose tolerance test, fasting blood glucose, obesity, family history of diabetes, women's health
- MeSH terms
- Adult, Analysis of Variance, Blood Glucose, Chicago, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glucose Tolerance Test, Humans, Insulin, Polycystic Ovary Syndrome, Regression Analysis, Testosterone, Prevalence, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
